Table 1

Clinicopathological features of breast cancer patients studied
n=96 Prior to chemotherapy After chemotherapy
Tumour size 1,5-13 cm 0,3-14 cm
cT1 1 (1%) ypT0 6 (6%)
-a ypT1 20 (21%)
-b -a 2
-c 1 -b 11
cT2 25 (26%) -c 7
cT3 22 (23%) ypT2 31 (32%)
cT4 41 (43%) ypT3 24 (25%)
-b 19 ypT4 7 (7%)
-d 22 -b 6
NA 7 (7%) -d 1
No surgery 8 (9%)
Lymph node status cN0 10 (11%) pN0 25 (26%)
cN1 62 (64%) pN1 27 (28%)
cN2 pN2 12 (12%)
cN3 3 (3%) pN3 14 (15%)
No surgery 8 (9%)
NA 21 (22%) NA 10 (10%)
ER status Positive 68 (71%) Positive 59 (62%)
Negative 25 (26%) Negative 16 (17%)
NA 3 (3%) NA 21 (21%)
ypT0, no surgery
PR status Positive 59 (62%) Positive 46 (48%)
Negative 34 (35%) Negative 29 (31%)
NA 3 (3%) NA 21 (21%)
ypT0, no surgery
HER2 status Positive 28 (29%) Positive 18 (19%)
Negative 65 (68%) Negative 57 (60%)
NA 3 (3%) NA 21 (21%)
ypT0, no surgery
Ki67 status 0 2 (2%) 0 22 (28%)
1 (0-1%) 12 (15%) 1 21 (27%)
2 (1-5%) 19 (23%) 2 11 (14%)
3 (5-10%) 13 (16%) 3 3 (4%)
4 (10-15%) 6 (7%) 4 1 (1%)
5 (15-20%) 4 (5%) 5 6 (8%)
6 (20-33%) 2 (2%) 6 1 (1%)
7 (33-50%) 4 (5%) 7 2 (3%)
8 (50-66%) 1 (1%) 8 0 (0%)
9 (66-80%) 3 (4%) 9 3 (4%)
10 (80-100%) 1 (1%) 10 2 (3%)
NA 14 (17%) NA 7 (9%)
64+17 (100%) 64+15 (100%)

NA: Accurate data are not available.

Teleki et al.

Teleki et al. BMC Cancer 2013 13:50   doi:10.1186/1471-2407-13-50

Open Data